Pharma BD Deal Intelligence
Eli Lilly's $3.19 billion acquisition of Morphic Holding landed an oral integrin inhibitor (MORF-057) built as a pill-form challenger to Takeda's injectable inflammatory bowel disease franchise. Lilly has since paired the asset with its own Omvoh in Phase 2 combination testing, though the drug remains years from a Crohn's or ulcerative colitis approval.
Lilly pays $3.2 billion to buy Morphic and deepen its immunology and gastroenterology portfolio, though the deal carries inherent Phase 2 risk with…
Eli Lilly acquired Morphic Holdings for $3.19B.
Phase 2 trial of LY4268989 (MORF-057) co-administered with mirikizumab (Omvoh) in moderately-to-severely active ulcerative colitis. Recruiting; started…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Eli Lilly acquired Morphic Holding for $57 per share in cash, approximately $3.19 billion, to gain MORF-057 (later LY4268989), an oral alpha4beta7 integrin inhibitor in Phase 2 development for ulcerative colitis and Crohn's disease positioned as an oral rival to Takeda's injectable IBD franchise. The deal deepened Lilly's immunology and gastroenterology portfolio; Lilly has since advanced the asset into a Phase 2 combination study with its own IL-23 antibody mirikizumab (Omvoh).
MORF-057 targets moderate-to-severe UC where oral advanced therapy is the key competitive positioning. Anti-alpha4beta7 integrin (direct MOA): Takeda's Entyvio (vedolizumab) remains the class benchmark with $5.5B FY2024 global sales; MORF-057's EMERALD-1 Phase 2b data (14% clinical remission at week 12) underperformed expectations and triggered pipeline risk. TNF inhibitors: Humira (adalimumab) biosimilars and Remicade (infliximab) biosimilars now represent commoditized first-line advanced therapy. IL-23 inhibitors (rising standard): AbbVie's Skyrizi (risankizumab, UC approved 2024) and Janssen's Tremfya (guselkumab, UC approved 2024) deliver high endoscopic improvement rates; Stelara (ustekinumab) is the established UC-approved IL-12/23. JAK inhibitors (oral class): Pfizer's Xeljanz (tofacitinib, ~$1.7B 2024 Pfizer inflammation franchise) and Rinvoq (upadacitinib, AbbVie, UC approved 2022) are the established oral options. S1P modulators (oral class): Bristol's Zeposia (ozanimod) and Pfizer's Velsipity (etrasimod, approved 2023) compete directly on oral convenience. For a commercial lead, MORF-057's franchise threat is diminished by soft Phase 2 efficacy — it enters a field where Skyrizi, Rinvoq, and Velsipity provide oral or high-efficacy options with established data, making Lilly's commercialization path contingent on Phase 3 rescue.
MORF-057 enters a crowded Crohn's space where oral convenience is the primary differentiation lever. Anti-alpha4beta7 integrin (direct MOA): Takeda's Entyvio (vedolizumab) is the IV/SC comparator with approximately $5.5B FY2024 global sales and established CD/UC indications; MORF-057 is the first oral alpha4beta7. TNF inhibitors: AbbVie's Humira (adalimumab) and biosimilars, Janssen's Remicade (infliximab), and Takeda's Entyvio dominate historical share; Humira alone generated $5.3B globally in 2024 post-biosimilar erosion. IL-23 inhibitors (rising standard): AbbVie's Skyrizi (risankizumab) produced $11.7B across indications in 2024 and has become the fastest-growing CD therapy with superior endoscopic remission data; Janssen's Stelara (ustekinumab) and Tremfya (guselkumab, CD approved 2025) extend the class. JAK inhibitors: Pfizer's Rinvoq (upadacitinib) is approved in moderate-to-severe CD post-TNF failure. S1P modulators: Bristol's Zeposia (ozanimod) has UC approval; CD development ongoing. MORF-057's commercial thesis is gut-selective oral delivery without JAK boxed warnings, but Skyrizi's efficacy bar and Entyvio SC availability make the window narrow. Lilly will need head-to-head differentiation on durability or steroid-free remission to capture share from IL-23 incumbents.
Morphic's preclinical integrin portfolio competes against an expanding small-molecule and antibody integrin field targeting fibrosis and autoimmunity. Oral small-molecule integrin inhibitors (direct class): Pliant Therapeutics' bexotegrast (PLN-74809, dual alphavbeta6/alphavbeta1, Phase 2b BEACON-IPF idiopathic pulmonary fibrosis and primary sclerosing cholangitis), Morphic's own MORF-057 (alpha4beta7, gastroenterology lead), and EA Pharma/Kissei's carotegrast methyl (AJM300, approved in Japan for UC) define the oral integrin category. Antibody integrin blockers: Takeda's Entyvio (vedolizumab, anti-alpha4beta7) posted FY2024 revenue of approximately $5.5B, setting the IBD ceiling; Biogen/Elan's Tysabri (natalizumab, anti-alpha4) remains in MS and Crohn's. Fibrosis-pathway comparators: Boehringer Ingelheim's Ofev (nintedanib, multi-TKI, approved IPF and SSc-ILD, EUR 4.2B 2024 sales) and Roche's Esbriet (pirfenidone) anchor antifibrotic standard of care without integrin selectivity. For a commercial lead, Morphic's preclinical pipeline is upside optionality on top of MORF-057 — Lilly's thesis requires the intEGRIN platform to deliver selective alphavbeta8, alphavbeta6, and alpha2beta1 assets able to erode Ofev's franchise or displace Entyvio's parenteral burden, but all remain discovery-to-IND stage.
Eli Lilly completed $3.19B acquisition of Morphic Holdings, gaining MORF-057, an oral integrin inhibitor for inflammatory bowel disease.
MORF-057 continued Phase 2 in UC and Crohn's disease, positioned as potential oral alternative to injectable biologics in IBD.
Post-close, Lilly rebranded MORF-057 as LY4268989 and expanded the program rather than shelving it: EMERALD-2 Phase 2b in ulcerative colitis (NCT05611671) reached primary completion Nov 2024 with results published 2025, and Lilly opened a new Phase 2 UC monotherapy trial (NCT07415044), a Crohn's Phase 2 (NCT06226883), and a combination study pairing the oral alpha4beta7 integrin with its own IL-23 antibody mirikizumab/Omvoh (NCT07186101). No trials terminated.
MORF-057 in mid-stage IBD development. $3.19B positions Lilly in GI inflammation alongside obesity/metabolic franchise. Clinical readout will determine value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Morphic Holdings (this deal) | 2024 | $3.2B | 62 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2024 deals · Eli Lilly and Company deals · Gastroenterology deals